Clinical Trial Update: A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A long-term extension Phase 2 study of the Alzheimer's vaccine ACC-001 with QS-21 in mild to moderate Alzheimer's disease was terminated, and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ACC-001
• QS-21 (Quillaja saponin)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 2 | Status: TERMINATED | Results posted: 2016-04-01